Authors
Eloïse Giabicani, Raphaëlle Billette de Villemeur, Mélodie Acher, Manon Cochet, Amélie Perrière, Béatrice Dubern, Irène Netchine
Published in
The Journal of clinical endocrinology and metabolism. Aug 19, 2025. Epub Aug 19, 2025.
Abstract
Silver-Russell syndrome (SRS) is an imprinting disorder characterized by severe intrauterine and postnatal growth retardation, feeding difficulties, and risk of hypoglycaemia. Recombinant growth hormone (rGH) therapy has shown its positive effect on adult height in SRS.
We aimed to assess the short-term effects of rGH therapy on the growth and nutritional status of these children.
Retrospective monocentric data of growth and nutritional characteristics of 77 prepubertal children with molecularly proven SRS during the first two years of rGH therapy were analysed.
The mean age at the initiation of rGH therapy was 3.7 (1.4-10.3) years. The mean height gain was 0.8 standard deviation score (SDS) after one year of treatment and 1.3 SDS after two years. The ideal weight for height (WfH), reflecting the nutritional status, increased from a mean of 81% at rGH initiation, to 84% after one year of treatment (p < 0.001) and 86% after two years (p < 0.001). The proportion of SRS children below a WfH of 75% decreased from 22.1% at rGH therapy initiation to 7.8% after two years of treatment. Starting rGH therapy before the age of four years was associated with a greater increase in height after two years, 1.5 vs 1.1 SDS, p = 0.012.
In prepubertal SRS children, the first two years of standard-dose rGH therapy significantly enhance both height and nutritional status. Early initiation of treatment, before the age of four years, further optimizes height gain.
PMID:
40827087
Bibliographic data and abstract were imported from PubMed on 19 Aug 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 36
- Comments 0